In June 2013, Elan's shareholders (Elan Corporation, NYSE: ELN) were faced with a difficult choice. Elan's management had four proposals on the table, management's attempt to defend itself against a hostile takeover from Royalty Pharma. Royalty Pharma was a private company, a private equity-owned collector of biotech and pharmaceutical royalties. If shareholders voted in favor of any of the four initiatives, it would likely kill Royalty Pharma's offer-and its guaranteed returns. That would allow Elan to stay independent, and remain under the control of a management team generally considered as underperforming.

【書誌情報】

ページ数：14ページ

サイズ：A4

商品番号：HBSP-TB0359

発行日：2013/12/1

登録日：2014/4/21